1
Clinical Trials associated with Atigotatug/NivolumabA Randomized, Double Blind, Multicenter Phase 3 Trial of BMS-986489 (BMS-986012+Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide vs Atezolizumab in Combination With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
The Purpose of the Study is to Compare the Efficacy and Safety of BMS-986489 (Anti-fucosyl-GM1+ Nivolumab Fixed Dose Combination) in Combination with Carboplatin plus Etoposide to that of Atezolizumab with Carboplatin plus Etoposide as First-Line Therapy in Participants with Extensive-Stage Small Cell Lung Cancer.
100 Clinical Results associated with Atigotatug/Nivolumab
100 Translational Medicine associated with Atigotatug/Nivolumab
100 Patents (Medical) associated with Atigotatug/Nivolumab
100 Deals associated with Atigotatug/Nivolumab